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Decamethylcyclopentasiloxane (D5) is a cyclic siloxane used in the formulation of consumer products as
well as an industrial intermediate. A summary of the previous studies on the toxicology of D5 is pro-
vided. Toxicokinetic studies with D5 after dermal administration demonstrate a very low uptake of due
to rapid evaporation. Following inhalation exposure, exhalation of unchanged D5 and excretion of me-
tabolites with urine are major pathways for clearance in mammals. Due to this rapid clearance by
exhalation, the potential for bioaccumulation of D5 is considered unlikely. The available toxicity data on
D5 adequately cover the relevant endpoints regarding potential human health hazards. D5 was not DNA
reactive or mutagenic in standard in vitro and in vivo test systems. D5 also did not induce developmental
and reproductive toxicity in appropriately performed studies. In repeated studies in rats with subacute,
subchronic and chronic inhalation exposure, mild effects on the respiratory tract typically seen after
inhalation of irritating materials, increases in liver weight (28- and 90-day inhalation studies), and a
small increase in the incidence of uterine adenocarcinoma (uterine tumor) in female rats (two-year
inhalation chronic bioassay) were observed. The liver effects induced by D5 were consistent with D5 as a
weak “phenobarbital-like” inducer of xenobiotic metabolizing enzymes and these effects are considered
to be an adaptive response. Mechanistic studies to elucidate the mode-of-action for uterine tumor in-
duction suggest an interaction of D5 with dopamine signal transduction pathways altering the pituitary
control of the estrus cycle. The resulting estrogen imbalance may cause the small increase in uterine
tumor incidence at the highest D5-exposure concentration over that seen in control rats. A genotoxic
mechanism or a direct endocrine activity of D5 is not supported as a mode-of-action to account for the
induction of uterine tumors by the available data.
© 2015 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Decamethylcyclopentasiloxane (D5), CAS 541-02-6, is a cyclic
siloxane used as an intermediate in the production of poly-
dimethylsiloxanes and has a number of secondary uses as a
component in consumer products. D5 has a low water solubility
(17 ppb) and a boiling point of 211 C. Due to the high volatility and
low surface energy, D5 readily volatizes. Therefore, inhalation and
dermal contact are the major expected routes of human exposures
to D5 for consumers, the general public and manufacturing
workers.
Extensive toxicity testing and experimental studies on D5 have
been performed addressing the acute, subchronic and chronic ef-
fects of D5 in rodents via dermal, oral and inhalation routes ofy, University of Würzburg,
W. Dekant), jklauni@indiana.
s article under the CC BY-NC-ND liexposure. The very limited dermal absorption (due to volatility)
and a speciﬁc toxicokinetic behavior after oral administration has
resulted in the selection of inhalation as the preferred route of D5
administration for toxicity studies. Several experimental studies
in vitro have also been performed with D5 to provide further in-
formation on the possible underlying mechanisms for the toxic
effects observed with D5 and the relevance of these effects in ro-
dents for human risk assessment.
This manuscript reviews and evaluates the results of the toxicity
and mechanistically based studies with speciﬁc interest in under-
standing the mechanisms by which D5 induces liver enlargement
and increases the incidence of the uterine adenocarcinomas after
chronic exposure in rats.2. Absorption, distribution, metabolism, and excretion of D5
The toxicokinetics of D5 are well characterized. Studies covering
both single and repeated inhalation exposures to D5, and followingcense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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experimental animals. In addition, human data on extent of dermal
absorption of D5 and the disposition of systemically available D5
have been generated (DCC, 1996; Burns-Naas et al., 1998a, 1998b;
DCC, 2002; DCC, 2003c; DCC, 2003d; DCC, 2003a; DCC, 2003b;
Varaprath et al., 2003; DCC, 2005a; DCC, 2007; Jovanovic et al.,
2008; Reddy et al., 2008; Tobin et al., 2008).
2.1. Absorption and distribution of D5 after inhalation exposures
The disposition of D5 was evaluated in male and female rats
after single and repeated inhalation exposures using nose only
inhalation (Tobin et al., 2008).
Rats were either exposed once for six hours to 7 or 160 ppm 14C-
D5 or, after 14 consecutive six hour nose-only exposures to
160 ppm of unlabeled D5 over two weeks, to a single six hour
exposure to 160 ppm 14C-D5 on day 15. D5-derived radioactivity
and parent D5 were quantiﬁed in blood, plasma, selected tissues,
expired air, urine, and feces collected at different time points. After
both single and repeated inhalation exposures, less then three % of
the delivered doses of D5 (calculation based on respiratory minute
volume, exposure duration, and D5 vapor concentration) were
retained in the animals. Signiﬁcant accumulation of D5 on the fur
was observed. Retained D5 was widely distributed from blood to
tissues with maximum concentrations observed in the majority of
the tissues three hours after exposure. In the plasma, liver and lung,
the majority of radioactivity immediately following exposure rep-
resented unchanged D5. However, the contribution of D5 to the
total radioactivity in tissues decreased over time and D5 repre-
sented only a small fraction of total radioactivity at time points
>24 h after the end of the exposure. Elimination of D5 and pre-
sumed metabolites from fat was slower as compared to plasma and
other tissues (DCC, 2001). Repeated exposure gave rise to higher
concentrations of parent D5 in the lung and fat of both sexes and in
the liver in female rats as compared to a single exposure.
Exhalation of unchanged D5 was the major pathway of elimi-
nation after both single and multiple inhalation exposures and
accounted for app. 50% of the retained D5. Elimination of D5-
derived radioactivity with urine in the form of metabolites
accounted for approximately 12% and fecal elimination for
approximately 16% of retained radioactivity. Fecal elimination of D5
may in part be due to oral ingestion of D5 deposited on the fur
absorbed during grooming. Elimination of D5-associated radioac-
tivity was multiphasic, but most of the radioactivity was eliminated
within 24 h after the end of inhalation exposure. As with other
lipophilic chemicals, fat may serve as a reservoir of D5 since little
decrease of D5-associated radioactivity in fat was observed over an
observation period of 168 h. Most of the radioactivity present in fat
was attributed to unchanged D5, a minor fraction was presumed to
represent a hydroxylated metabolite (Tobin et al., 2008).
Analysis of the fecal extracts by high-pressure liquid chroma-
tography (HPLC) indicated that the majority of the radioactivity in
feces was unchanged D5, a hydroxylated derivative of D5 was a
presumed minor metabolite. HPLC-analysis of urine samples
revealed the presence of seven metabolites. The two major me-
tabolites were dimethylsilanediol and methylsilane triol with
[MeSi(OH)2eOeSi(OH)3], [MeSi(OH)2eOeSi(OH)2Me],
[MeSi(OH)2eOeSi(OH)Me2], [Me2Si(OH)eOeSi(OH)Me2], and
[Me2Si(OH)eOSiMe2eOSi(OH)Me2] representing minor metabo-
lites (Varaprath et al., 2003). The metabolite structures suggest that
D5 is initially oxidized to a hydroxylated derivative, presumable by
cytochrome P450 (Fig. 1). This initial metabolite appears to rear-
range and downstream products are degraded by hydrolysis to the
short-chain siloxanes, which are excreted (Fig. 1).
The toxicokinetics of D5 after inhalation exposure were alsostudied in human subjects (three males and two females) after
inhalation of D5 at a single concentration of 10 ppm for one hour
using a mouthpiece exposure system under a mixed rest/exercise
scheme (DCC, 2004c). During exposure, D5 concentrations in
exhaled air rapidly reach a steady state between 7 and 10 ppm;
after the end of the exposures, D5 levels in exhaled air rapidly
declined and reached concentrations of less than 1 ppm within
20 min in most of the subjects. Concentrations of D5 in plasma
increased from a baseline level of 0.15e3.3 mg/L to between 31 and
70 mg/L at the end of the inhalation exposure and rapidly declined
after the end of the exposure to reach the basal levels within 24 h
after the termination of the inhalation exposure (DCC, 2004c).
2.2. Bioavailability and deposition of D5 after dermal
administration
Toxicokinetics of D5 after dermal exposure were assessed in
humans and in rats. In addition, the dermal absorption of D5 was
studied in a number of in vitro studies (Jovanovic et al., 2008).
Three male and three female human subjects applied 1.4 g
(males) or 1.0 g (female) of 13C-D5 to the axilla under unoccluded
conditions. Blood samples were collected for up to six hours and
exhaled air samples were collected for up to 24 h after application
(DCC, 2002). Peak concentrations of 13C-D5 in the plasma were
achieved within two hours after application and were 1.22 ng/g at
one hour, 0.61 ng/g at six hour sampling, and were below the limit
of detection of 0.03 ng/g in all samples taken later than six hours
after 13C-D5 application. Concentrations of 13C-D5 in exhaled air
were below one ng/L at all time points.
14C-D5 was applied under semi-occluded conditions to human
skin from six donors using a ﬂow-through diffusion cell technique
with provisions to collect material volatilized from the skin by
absorption to charcoal traps. Skin samples were dosed either with
neat D5 or with a generic antiperspirant formulation containing D5.
After 24 h, only 0.04% of the applied dose of neat D5 and 0.022% of
the D5 present in the formulationwas absorbed. Themajority of the
applied D5 was volatilized from the skin samples and was recov-
ered on the charcoal traps (DCC, 1999). The cumulative penetration
for neat D5 was 0.1 mg/cm2 and 0.3 m/cm2 for formulated D5.
To assess the fate of D5 absorbed from the skin in intact animals,
14C-D5 was applied to the dorsal surface of male and female rats.
Hair at the application site was clipped prior to application and the
application site was covered with a non-occlusive elastic wrap. The
study was designed to permit differentiation between D5 exhaled
after absorption and D5 evaporating from the application site. After
application of D5, the animals were transferred to metabolic cages
for the collection of urine and feces. The majority (about 85%) of the
applied 14C-D5 volatilized from the skin. After 96 h, 0.35% of the
administered D5 remained at the application site and less than 1%
of the applied 14C-activity was recovered in urine and carcass with
trace levels of 14C-activity recovered in feces, CO2 traps, and tissues.
The total amount of D5 absorbed was <1% (DCC, 2003c).
2.3. Toxicokinetics of D5 after oral administration
Toxicokinetic studies were performed in rats after dosing by
gavage with 14C-D5 (single dose of 1000 mg/kg bw) dissolved in
different vehicles (corn oil and simethicone ﬂuid) and as a neat
material (DCC, 2003a). The carrier had a signiﬁcant inﬂuence on the
extent of absorption of 14C-D5. After administration of neat D5,
approximately 10% of the dose was absorbed from the gastroin-
testinal tract. Based on blood area under the curve (AUC), absorp-
tion increased after administration of D5 in corn oil and decreased
after administration in simethicone ﬂuid. Elimination half-lives for
D5-associated radioactivity in blood ranged from 45 (simethicone)
Fig. 1. Biotransformation of D5 in rodents.
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(simethicone) for parent D5. The radioactivity eliminated in the
urine consisted entirely of polar metabolites of D5. Mass balance
analysis indicated that approximately 60e80 % of the administered
D5 was excreted unchanged in the feces, and up to 20% of admin-
istered D5 as water soluble metabolites in urine. Half of the sys-
temically available D5 was eliminated as unchanged D5 in exhaled
air. However, the kinetics and tissue distribution observed after oral
dosing were qualitatively different from the distributions after
inhalation or dermal exposures. Higher relative concentrations of
D5were noted in liver and spleen as compared to exposure to D5 by
inhalation and dermal application.2.4. Physiologically based toxicokinetic modeling
The toxicokinetic data obtained in studies after D5 inhalation or
after dermal application were used as a basis to develop and
evaluate physiologically based toxicokinetic models (PBTK). The
lipophilicity and volatility of D5 have a major inﬂuence on the
toxicokinetics. The high lipophilicity results in high lipid parti-
tioning and in retention of D5 in blood lipids. This is the cause of the
differences in kinetic behavior after inhalation and dermal
administration as compared to oral dosing. Due to the high vola-
tility, D5 is rapidly cleared from blood by exhalation. Hepatic
clearance by biotransformation of D5 to polar metabolites also
occurs.
Inhalation and dermal administration result in a similar phar-
macokinetic proﬁle, presumably due to diffusion of D5 molecules
through membranes. At the onset of inhalation, blood levels of D5
climb rapidly and equilibrium between inhalation and exhalation
of unchanged D5 is rapidly reached. Only a relatively small amount
of the inhaled D5 is retained. In blood, D5 may exist in a free pool
available for exhalation and biotransformation and a sequestered
pool associated with blood lipids. During dermal exposures, D5 is
rapidly absorbed into the outer layers of skin, but readily evapo-
rates before signiﬁcant systemic absorption occurs. Physiologically
based toxicokinetic modeling of the percutaneous absorption data
from the human dermal absorption study predicts the dermal ab-
sorption of D5 as 0.05% (Reddy et al., 2007). Due to the efﬁcient
clearance of D5 by exhalation, approximately 90% of the D% sys-
temically available after dermal application is exhaled.The distribution and kinetics of D5 after oral dosing differed
signiﬁcantly from the predictions of the PBTK model that well
described the inhalation and dermal exposure routes (Reddy et al.,
2007, 2008). The differences in toxicokinetics after oral adminis-
tration as compared to inhalation or skin contact suggest that D5 is
transferred from the gastrointestinal tract to the blood by different
mechanisms as compared to those operative after inhalation or
dermal administration. The oral route may deliver microemulsions
of D5 that do not readily dissolve in plasma and blood and are
distributed as such. Uptake may be more associated with lipid
transport, such as chylomicron formation and thus D5 may not be
completely available for tissue interactions. The microemulsions
may be removed from the circulation by the reticuloendothelial
system in liver and spleen.
The oral dosing studies suggested a much higher persistence of
D5 in blood compared to inhalation and dermal dosing. However,
this apparent persistence after oral dosing is most likely due to the
fact that a fraction of D5 is present in a pool that is unavailable to
interact with tissues. These differences in toxicokinetics indicate
that results from toxicity studies with D5 using oral dosing in oil
vehicles likely have little relevance for assessing human health
risks of D5 after inhalation and dermal exposures.
PBTK models also predict that D5 has no tendency to accumu-
late after repeated dosing. Absence of a potential for bio-
accumulation is also indicated by an absence of an increase in D5-
tissue concentrations after a 6-month inhalation exposure per-
formed as a segment of the chronic bioassay (DCC, 2005b). While
D5 is very lipophilic with fat:blood partition coefﬁcients between
500 and 1,000, it is readily eliminated by exhalation or by
biotransformation to polar metabolites.3. Toxicity of D5
3.1. Acute and repeated dose toxicity
D5 has a low potential for toxicity after single oral administra-
tionwith no overt signs of adverse effects after a single gavage dose
of 5 g/kg bw. Therefore, the oral LD50 > 5000mg/kg bw. After single
aerosol inhalation exposures, the four hour LC50 is 560 ppm. D5 is
not an eye or skin irritant in standard animal studies. D5 is not a
skin sensitizer in animals or in humans.
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assessed after repeated dermal, oral, and inhalation exposure.
Repeated dose dermal studies with D5 were performed for dura-
tions of up to 28 days (rats) or 21 days (rabbits) under occlusive
conditions. These studies have performed detailed histopatholog-
ical evaluation of a number of tissues at sacriﬁce and included
analysis of clinical chemistry parameters, hematology, body weight
gain and food consumption. Effects related to D5 treatment were
not observed up to applied nominal doses of 1600 mg/kg bw (rats)
or 1000mg/kg bw (rabbits) to the skin. The lack of effects in toxicity
studies using dermal exposure is consistent with a minimal dermal
penetration of D5 (HRS, 1979; DCC, 1990b).
The oral toxicity of D5 was studied after repeated dosing for
both 28 and 90 days (Table 1). Liver weight increases were reported
in both studies. These were accompanied by an increased incidence
and a dose-related increase in severity of periportal lipidosis in
females in the 28-day study. In male rats, the liver weight changes
were not accompanied by histopathological changes. In the 90-day
study, increased liver weights without histopathological changes
were reported for both male and female animals. In addition, no
histopathological effect of D5-administration on the other organs
examined nor effects on body weight gain, food consumption and
clinical chemistry were reported (DCC, 1990a; REACH, 2011)
(Table 1).
Due to the high volatility of D5, the very limited dermal ab-
sorption, and the speciﬁc processes of D5 uptake after oral
administration, the pivotal toxicity studies relevant for hazard
assessment of D5 used inhalation as the route of exposure. This
exposure regimen results in higher systemic exposure as compared
to dermal application. However, since the saturated vapor con-
centration of D5 is approximately 180 ppm, the maximum vapor
concentrations of D5, which can be reproducibly produced without
interference by aerosol formation, are around 160 ppm. These
physicochemical properties of D5 limit the maximum vapor expo-
sure concentrations achievable in inhalation exposures (Burns-
Naas et al., 1998b) and results obtained in studies using higher
concentrations of D5 in air have to be evaluated with caution due to
the potential formation of aerosols and associated issueswith doses
delivered. The results of the available inhalation studies with D5 are
compiled in Table 2.
In a 28-day study (RCC, 1995a) and a 90-day inhalation studies
(RCC, 1995b; Burns-Naas et al., 1998b), nose-only exposure was
used. The highest concentrations applied were a mix of D5 vapor
and aerosol; in addition, a 28-day study and a 90-day study used
whole-body exposures and exposure was to D5 vapor only (Burns-
Naas et al., 1998a). The 28-day studywith whole body exposure and
both 90-day studies included recovery groups to assess the
reversibility of potential effects resulting from D5 inhalation.
In all inhalation studies with D5, besides slight local effects on
the respiratory tract, increased liver weights were observed and
slight liver damage was also indicated by clinical chemistry pa-
rameters (Table 2). However, the liver weight changes were not
accompanied by histopathological changes in the liver and were
reversible. The respiratory tract was the other major target organTable 1
Summary of oral toxicity studies with decamethylcyclopentasiloxane (D5) after oral adm
Animal model Study design and dosing NOAEL/LOEL
SpragueeDawley
rats
28-day oral toxicity study using doses of 0, 25,
100, 400 and 1600 mg/kg bw, 5 days/week;
NOAEL 100 mg/kg
in males, no NOAE
SpragueeDawley
rats
90-day oral toxicity study using doses of 0,
100, 330 and 1000 mg/kg bw, 5 days/week;
NOAEL of >1000 m
bw/dayafter D5 inhalationwith exposure-related increases in absolute and
relative lung weights, which remained elevated in females after the
recovery phase. In addition, small increases in focal macrophage
accumulation (both after 28-day and 90-day exposures) and
interstitial inﬂammation (90-day exposure) were seen in the lungs
of both male and female animals in the high concentration groups.
In the 28-day study, D5 exposure also resulted in an increase in
incidence and severity of goblet cell proliferation in the nasal cavity
in both sexes at 160 ppm. Initially, histopathological effects were
not reported in the other organs examined (Burns-Naas et al.,
1998b). However, a detailed review of tissues potentially sensitive
to D5 as indicated by the results of the 2-year inhalation chronic
bioassay demonstrated slight changes in high dose female animals
(160 ppm) from the 90-day study at terminal sacriﬁce. These
included increased mean number of atretic, antral-sized follicles/
animal, increased incidence and severity of vaginal muciﬁcation,
and an increased incidence of male-type acinar development of the
mammary gland. In the animals sacriﬁced after the recovery period,
10/10 animals in the control group and only 5/10 high dose animals
had resumed normal estrous cycles. Most were in diestrus II but
showed evidence of recent cycling. In addition, vaginal muciﬁcation
and clear cell changes remained increased in the high-dose re-
covery animals andmale-type acinar development persisted in two
animals exposed to D5 (DCC, 2006).
D5 was also tested for carcinogenicity in a two year combined
chronic toxicity/carcinogenicity study (chronic bioassay) by inha-
lation in male and female F344 rats (DCC, 2005b). The study was
split in a main group (chronic, 24 month exposure) and three sat-
ellite groups exposed to D5 for different durations (6 months, 12
months and 12 months plus a 12 month recovery) (Table 2). An
increased incidence of hyaline inclusions in the nasal cavity in both
males and females exposed to 160 ppm D5 for six months were
noted. Statistically signiﬁcant increases in liver weights were seen
at 6 and 12 months in females and at 24months in males, but these
increases were neither D5-concentration nor exposure duration
related. Increased incidences of respiratory tract irritationwere also
observed in one or both sexes at the 6, 12, and 24months sacriﬁces.
In the animals of the main group (24 month exposure) and the
recovery group (12 months exposure followed by 12 months re-
covery) sacriﬁced after 2 years, hyaline inclusions in the nasal
cavity were seen in both males and females at 160 ppm and in
males at the 40 ppm exposure levels. However, effects indicative of
irritation (e.g., inﬂammatory cell inﬁltration or degenerative
changes in the epithelium) were not observed.
The incidences of neoplastic changes were not statistically
signiﬁcantly different in males for all analyzed tissues and in fe-
males for all tissues except the uterus. In female F344 rats, inha-
lation exposure to D5 induced a small increase in the incidence of
uterine endometrial adenocarcinoma at the highest exposure dose
(160 ppm). This increase was statistically signiﬁcant when all
exposure levels (trend analysis) were included in the analysis
(Table 2) but not signiﬁcant when examined pair wise to the control
rats. In addition, a signiﬁcant decrease in the incidence of cystic
changes in the clitoral gland was observed in the 160 ppm groupinistration.
Observations Reference
bw/day
L in females
Increases in absolute liver weight
in males and females at doses > 100 mg/kg
bw/day, slight, but not statistically signiﬁcant
increase in liver weight at 25 mg/kg bw in females
(DCC, 1990a)
g/kg Signiﬁcant increases in liver weights at all dose
levels in males and females without
histopathological changes.
(REACH, 2011)
Table 2
Summary of results from key toxicity studies on Decamethylcyclopentasiloxane (D5) using inhalation as route of exposure.
Animal model Study design and dosing NOAEC/LOEC Observations Reference
Fischer F344 rats 28-day inhalation toxicity study with whole body
exposure to 0, 10, 25, 75 and 160 ppm D5 for 6 h/day, 7
days/week; groups of 10 males and 10 females/group
including recovery group of 5 male and 5 female rats
observed for 14 days after termination of exposure
NOEC of 10 ppm for
local effects in the
respiratory tract;
75 ppm for liver
weight increases
Increased liver weight in male and female
animals at 160 ppm, increased mean lung
weight and alveolar macrophage accumulation
at 160 ppm, morphological alterations in nasal
cavity at >10 ppm. Liver weight changes
reversible
(Burns-Naas et al.,
1998a)
Fischer F344 rats 28-day inhalation toxicity study with nose only
exposure to 0, 32, 50, 105, and 148/239 ppm D5 for 6 h/
day, 5 days/week; groups of 10 males and 10 females/
group including recovery group of 5 male and 5 female
rats observed for 14 days after termination of exposure
NOEC of 105 ppm
for liver weight
increases
Increased liver weight in females at 148/
239 ppm, reversible after 14-day recovery;
changes in hematology parameters highest
concentration in females, reversible after 14-
day recovery period, liver and lung weight
increases at high concentration, increase in
incidence and severity of goblet cell
proliferation in nasal cavity in males and
females at highest concentration, increased
incidence of hepatocellular hypertrophy at
highest concentration in males and females
(RCC, 1995a)
Sprague Dawley
rats
90-day inhalation toxicity study with whole body
exposure to 0, 20, 60 and 120 ppm D5 for 6 h/day, 7
days/week; groups of 10 males and 10 females/group
including recovery group of 10 male and 10 female rats
exposed to 0 and 120 ppm observed for 28 days after
termination of exposure
NOEC of 60 ppm for
liver weight
increases (female)
Statistically signiﬁcant increase in relative liver
weight at 120 ppm in females, no effect in
males; no difference in liver weights after 28
days recovery period
(DCC, 1990a)
Fischer F344 rats 90 day inhalation study with nose-only exposure to
targeted concentrations of 0, 29, 46, 92, and 223 ppmD5
for 6 h/day, 5 days/week; groups of 20 male and 20
female rats including additional recovery group of 10
male and 10 female rats exposed to 0 and 223 ppm
observed for 28 days after termination of exposure
NOEC of 46 ppm for
liver weight
increases (females)
Signiﬁcant increases in liver weight in females
at 46 and above and at 223 ppm in males;
increased lung weights at 223 ppm; increased
incidence of alveolitis in males and females at
92 and 223 ppm, increased incidence of ovarian
interstitial gland hyperplasia and vaginal
mucosal muciﬁcation and atrophy in females at
223 ppm; lung weights remained elevated in
females after recovery phase.
dose-related increases in g-glutamyltransferase
(>26 ppm) and serum lactate dehydrogenase
(>46 ppm) not resolved during recovery;
(DCC, 1990a; RCC,
1995b; Burns-Naas
et al., 1998b)
Fischer F344 rat 2-year inhalation study with whole body exposure to 0,
10, 40, and 160 ppm D5, 6 h/day, 5 days/week, main
group with exposure for 2 years consisted of 60
animals/sex/D5 concentration
Groups of 10 animals/sex/D5 concentration exposed for
one year with immediate sacriﬁce
group of 20 animals/sex/D5 concentration exposed for
one year with sacriﬁce one year after termination of
exposure
group of 6 animals/sex/d5 sacriﬁced after 6 month, used
mainly for calibration of Pk model
NOAEC of 160 ppm
for systemic, non-
neoplastic effects
Increased incidences of endometrial
adenocarcinoma (0, 1, 0, 5) in the 0, 10, 40, and
160 ppm exposure groups after 2 year
inhalation exposure
No effects observed after one year inhalation
and immediate sacriﬁce
Endometrial adenomatous polyps and
endometrial adenocarcinoma (combined
incidences of 1, 1, 0, 3) in the 10, 40, and
160 ppm exposure groups after 1 year
inhalation exposure to D5 and one year of
recovery
No histopathological effects after 6 month of
exposure
(DCC, 2005b)
SpragueeDawley
rats
One-generation reproductive toxicity study by whole
body inhalation to 0, 26, and 132 ppm D5 for 6 h/day for
a min. of 28 days prior to mating and through the day of
sacriﬁce (22 male and female animals/group).
Exposures of females suspended from GD 21 to
lactational day 4, offspring examined after sacriﬁce on
PND 28
NOAEC of 132 ppm No effects on food consumption, body weight
gain, reproductive parameters (fertility, mating,
days between pairing and coitus, gestation and
parturition). Mean numbers of implantation
sites and mean live litter size. No effects on pup
viability, pup sex ratios and mean pup weights
(WIL, 1996)
SpragueeDawley
rats
2-generation reproductive toxicity study by whole body
inhalation to 0, 30, 70, and 160 ppmD5 for 6 h/day for at
least 70 consecutive days prior to mating through
weaning of pups on postnatal day 21 performed in
accordance with US EPA OPPTS Health Effects Test
Guideline 870.3800
Overall NOAEC of
160 ppm
No effects on reproductive parameters, no effect
on developmental parameters
(Siddiqui et al.,
2007)
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of the mammary gland area (0 ppm, 8/60; 10 ppm, 7/60; 40 ppm, 7/
60; 160 ppm, 2/60) was indicated.
3.2. Reproductive and developmental toxicity
The reproductive and developmental toxicity of D5was assessed
in a one-generation reproductive toxicity study and in a two-
generation reproductive and developmental toxicity study in rats.The two-generation study included an assessment of develop-
mental neurotoxicity (Table 2). In all reproductive and develop-
mental toxicity studies, the animals were exposed to D5 by
inhalation at concentrations up to 160 ppm.
In the two-generation study, the F0 and F1 female rats were
exposed throughout mating and through gestational day 20 when
exposures were stopped to allow parturition and to permit
continuous maternal care for the neonates. Exposures were
resumed on lactation day 5 and continued until the day prior to
W. Dekant, J.E. Klaunig / Regulatory Toxicology and Pharmacology 74 (2016) S67eS76S72sacriﬁce. F2 pups were not exposed to D5. All F0 and F1 females
were allowed to deliver and rear their pups until weaning on
lactation day 21. Offspring (30/sex/group) from the pairing of the F0
animals were selected as the F1 generation. Neonatal survival,
growth, and development of the F1 and F2 generations and devel-
opmental landmarks (balanopreputial separation and vaginal
patency) were evaluated for the selected F1 rats. Thirty pups/sex/
group from the F2 generation were selected for examination of
development landmarks, neurobehavioral testing, neuropathology
brain weights, and/or brain dimension measurements. Surplus F1
and F2 pups were necropsied on PND 21 or 28, and selected organs
were weighed. Selected F2 rats not allocated for neuropathology
and brain dimension measurements were necropsied on PND 70.
All surviving F0 and F1 parental animals were subjected to gross
necropsy following the completion of weaning of the F1 and F2
pups. Evaluations of sperm parameters were performed in all F0
and F1 males, and ovarian primordial follicle and corpora lutea
counts were recorded for F0 and F1 females in the control and the
highest exposure concentration (160 ppm). Designated tissues from
all F0 and F1 parental animals in the control and 160 ppm groups
and from F2 pups selected for neuropathological evaluation were
examined microscopically (Siddiqui et al., 2007).
D5 inhalation did not affect any of the assessed reproductive
parameters and had no effects on body weights, body weight gain,
and organ weights in the F0 and F1 generations. In addition, the
functional observational battery in F1 females did not show D5-
induced effects on gestation day 10 and lactation day 20. D5
inhalation did not induce effects on the parameters determined to
assess reproductive performance or potential developmental ef-
fects. The only statistically signiﬁcant effect was an increase in
anogenital distance in male F1 pups, but not male F2 pups or in F1
and F2 female pups. Developmental landmarks in F1 and F2 and F2
neurobehavioral responses were not affected by parental exposure
to D5 and neither microscopic ﬁndings nor differences in mean
brain weights and brain measurements were noted.
4. Genotoxicity of D5
Multiple assessments of genetic toxicity have been performed
with D5 (Litton,1978; Isquith et al., 1988; DCC, 2003d; DCC, 2004d).
The genotoxicity of D5 was evaluated in bacteria, cultured
mammalian cells, and in rats after D5 inhalation (Table 3). D5 did
not show a genotoxic response when assessed for gene mutation in
bacteria and in mammalian cells and did not induce structural
chromosome aberrations (Table 3). The mutagenic potential of D5
was also assessed in vivo using unscheduled DNA Synthesis (UDS)
in hepatocytes and induction of micronuclei in bone marrow (DCC,
2004b) after whole body inhalation exposure (160 ppm, 6 h/day for
7 consecutive days) in rats (Table 3). In these studies, positive
controls (2-acetylaminoﬂuorene for the UDS and cyclophospha-
mide in themicronucleus assays) were concurrently performed and
produced the expected response. In the combined UDS/micronu-
cleus assay, animals were sacriﬁced ﬁve and 16 h after the last
inhalation exposure, and UDS was determined in primary hepato-
cytes. D5 did not induce UDS as compared to concurrent air con-
trols. In bone marrow cells collected 24 h after the last inhalation
exposure for micronucleus analysis, D5 did not cause bone marrow
toxicity or increase the frequency of micronuclei.
5. Results from mechanistic studies with D5
5.1. Hepatomegaly and enzyme induction
The results of a number of repeated-dose toxicity studies with
D5 resulted in a reversible hepatomegaly in rats. Several studiesinvestigated the mechanistic basis for this effect (McKim et al.,
1999; DCC, 2000a; Zhang et al., 2000; DCC, 2004e; DCC, 2004f).
Most of these studies focused on enzyme induction as the potential
mechanism for the liver weight increases. Enzyme activity and
relative protein concentrations of cytochromes P4501A, 2B, 3A, and
4A), epoxide hydrolase, and UDP-glucuronyl transferase (UDPGT)
were determined in liver microsomes obtained from female F344
rats exposed to D5 by inhalation for six hours/day and ﬁve days/
week over 28 days. This exposure regimen increased liver size by
16% relative to controls. The increase in liver size in D5-exposed
animals was partly reversed after a 14-day recovery period. Over-
all P450 activity in liver microsomes was not inﬂuenced by D5
inhalation; however, D5 inhalation resulted in small increases in
the activity of NADPH-cytochrome c reductase and 7-
ethoxyresoruﬁn O-deethylase activity (EROD), but without an
accompanying increase in the concentrations of the CYP1A1/2
protein. CYP1A1/2 is the major P450 enzyme that catalyzes EROD
activity. A fourfold increase in 7-pentoxyresoruﬁn 0-depentylase
activity (PROD) and a threefold increase in the relative concentra-
tions of CYP2B1/2 protein were also observed. In addition, testos-
terone 6b-hydroxylase activity and CYP3A1/2 protein
concentration were increased. The levels of CYP4A were un-
changed, but a small increase in 11- and 12-hydroxylation of lauric
acid was detected. D5-exposure also caused moderate increases in
liver microsomal epoxide hydrolase protein concentration and ac-
tivity. UDPGT activity was increased with chloramphenicol but not
with 4-nitrophenol as substrate. These observations suggest that
D5 acts as a “phenobarbital-like” inducer since the enzyme in-
duction proﬁle caused by D5 inhalation is similar to that reported
for phenobarbital (McKim et al., 1999).
A direct comparison of the liver enzyme induction proﬁle of D5
to that of phenobarbital used repeated oral administration of D5 at
dose levels up to 100 mg/kg bw for four consecutive days and
compared the liver enzyme proﬁle to that induced by a single
intraperitoneal dose of Phenobarbital. Relative liver weight was
increased by D5 at the highest dose. In liver microsomes isolated
from D5-treated rats, concentrations of CYP2B1/2 protein were
signiﬁcantly increased at D5 doses >5 mg/kg bw with a parallel
increase in PROD activity in females at doses >5 mg/kg bw and in
males at 20 and 100 mg/kg bw. In addition, EROD activity was
increased in males and females at doses of above 5 mg/kg bw, but
without changes in CYP1A1/2 concentrations. Increases in relative
concentrations of the CYP3A1/2 protein also occurred in males at
100mg/kg bw and females at D5 doses above 5mg/kg bw. The P450
reductase protein was signiﬁcantly induced at 5 mg/kg bw in
males and 20 mg/kg bw in females. A similar induction pattern
was observed with phenobarbital (Zhang et al., 2000) further
conﬁrming the ability of D5 to act as a “phenobarbital-like” inducer.
In incubations with human livermicrosomes, the potential of D5
(0.040e3.5 mM) as a reversible or irreversible inhibitor of several
P450 enzymes was evaluated. D5-mediated inhibition of CYP1A2,
CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP4A9/
11 activity was not observed. D5 was only a weak competitive in-
hibitor of human CYP3A4/5, but a potent metabolism-dependent
inhibitor of human CYP3A4/5 (DCC, 2000b). For comparison, D5
was a potent reversible metabolism-dependent inhibitor of rat
CYP1A1/2 activity but did not inhibit rat CYP2B1 activity.
5.2. Estrogenicity
The potential estrogenicity of D5 was assessed in vivo and in
in vitro binding studies to the estrogen receptor (DCC, 2004e; DCC,
2004f; DCC, 2004g; DCC, 2004h; DCC, 2004a). In intact animals,
estrogenic effects of D5 were assessed in an uterotrophic assay in
both SpragueeDawley and Fischer 344 rats after D5 inhalation
Table 3
Summary of results from genotoxicity testing with D5.
System Experimental conditions Endpoint assessed Results Reference
In vitro Salmonella typhimurium (TA-1535, TA-1537, TA-
1538, TA-98, and TA-100)
Escherichia coli (W3110/polAþ, P3478/polA-)
Concentrations up to 5 mg/plate, with
and without metabolic activation
Gene mutations negative (Litton, 1978)
In vitro Escherichia coli polAþ Concentrations up to 5 mg/plate DNA-repair negative (DCC, 2003c)
In vitro Cultured mammalian cell (mouse lymphoma) Concentrations up to 6.4 ml/ml with and
12.5 without metabolic activation
Gene mutation negative (Isquith et al., 1988)
In vitro Cultured mammalian cell (mouse lymphoma) Concentrations up to 25 ml/ml with and
without metabolic activation
Chromosome aberration negative (Isquith et al., 1988)
In vitro Cultured mammalian cell (Chinese hamster V79) Concentrations up to with and without
metabolic activation
Chromosome aberration negative (Isquith et al., 1988)
In vitro Cultured mammalian cell (mouse lymphoma) Concentrations up to 25 ml/ml with and
without metabolic activation
Sister chromatid exchange negative (Isquith et al., 1988)
In vitro Cultured mammalian cell (mouse lymphoma) Concentrations up to 25 ml/ml with and
without metabolic activation
Alkaline elution assay for
general DNA-damage
negative (Isquith et al., 1988)
In vivo Primary hepatocytes from rats Isolated from rats exposed to D5 by
inhalation (160 ppm, 6 h/day, 7 days)
Unscheduled DNA-synthesis negative (DCC, 2004a)
In vivo Bone marrow cells from rats Isolated from rats exposed to D5 by
inhalation (160 ppm, 6 h/day, 7 days)
directly after the end of the inhalation
exposure
Micronucleus formation negative (DCC, 2004a)
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sacriﬁced immediately following the last exposure. No effects of
D5-exposure on wet and blotted uterine weight were observed. D5
was also negative in a Hershberger assay (a short-term in vivo assay
to detect androgenic or antiandrogenic chemicals or chemicals that
inhibit 5a-reductase).
In an additional study to assess a role of membrane and nuclear
estrogen receptors in a potential estrogenic response of D5 in ani-
mals, rats were exposed by inhalation to D5 (whole body, 160 ppm
for 6 or 16 h) and possible D5-mediated effects on estrogen-
dependent endpoints were compared to the responses induced
by ethinylestradiol (activates both the membrane and nuclear ER)
and 4-hydroxytamoxifen (activates membrane ER but is a partial
agonist/antagonist for nuclear ER). The study determined uterine
weight (wet and blotted), estrous state, epithelial cell height
(luminal and glandular), histopathology (uterus and mammary
gland) and cell proliferation in luminal, glandular, stromal and total
cells of the uterus and mammary gland epithelium. Both positive
controls resulted in the expected response, but D5 did not inﬂuence
any of the estrogen responsive parameters measured (DCC, 2012).
In vitro, D5 (0.28 mM) did not show a capacity to compete with
estradiol for binding to the estrogen receptor. D5 (10 mM) also did
not give a response in a reporter gene assay using MCF-7 cells
transiently transfected with a plasmid for estrogen receptor alpha
and the luciferase gene. D5 did not interact with progesterone re-
ceptors alpha and beta (Quinn et al., 2007).
5.3. Dopamine agonism
A series of experiments investigated the ability of D5 to act as
dopamine agonist and effect prolactin secretion. Such a mode-of-
action may explain the formation of uterine tumors in rats
observed after inhalation to 160 ppm D5 for two years (Klaunig
et al., 2015). Dopamine agonists inhibit prolactin secretion from
the pituitary in rats causing estrogen dominance, and results in
persistent endometrial stimulation leading to endometrial tumors.
Studies investigating a possible role of dopamine agonism were
performed in two animal model systems and in a series of in vitro
systems (DCC, 2005d; DCC, 2005e; DCC, 2010a; DCC, 2010b; DCC,
2011). The reserpine pretreated rat and the aging Fisher F344 rat
were used as animal model systems. Reserpine administration to
rats depletes brain dopamine (Metzger et al., 2002), which blocks
the dopamine inhibition of prolactin secretion into blood andresults in a pronounced increase in circulating prolactin. Adminis-
tration of dopamine D2 receptor agonists following reserpine
administration will decrease prolactin. Therefore, this model is
often used to investigate the potential for a chemical to interact
with the dopamine D2-receptor in vivo (Graf et al., 1976; Horowski
and Graf, 1976). In the aging F344 rat, altered hypothalamic control
of dopamine causes an elevated prolactin secretion and results in
increased prolactin levels in blood. Administration of dopamine
receptor agonists also reduces prolactin in this system.
Support for D5 as a dopamine agonist was examined in rats
treated with D5 by inhalation and reserpine (DCC, 2005c). In
reserpine-treated rats, D5-exposure (nose-only inhalation,
160 ppm for six hours) reduced the reserpine-induced increase in
prolactin levels by 50% (DCC, 2005c). The dopamine receptor
antagonist sulpiride blocked the prolactin-lowering effect of D5.
In another study, a time course exposure of D5 on prolactin
concentrations was investigated in reserpine-pretreated female
rats, since effects on dopamine may only occur during and shortly
after the end of D5 exposures due to the rapid clearance of D5 by
exhalation. The study design used Pergolide in a positive control
group. In this study, serum prolactin levels were not decreased in
reserpine-treated rats at the end of the six hour exposure to
160 ppm D5 and at four hours after the end of the inhalation
exposure. At eight hours after exposure, levels of serum prolactin
were decreased in the D5 group by 36% as compared to reserpine
controls (not statistically signiﬁcant). Decreases in serum prolactin
levels were most prominent after the 18-h post-exposure time
point in the D5 exposed group. At this time, circulating serum
prolactin levels were returning to normal due to a loss of the
reserpine effect. Prolactin levels in the D5 exposed group were
similar to the reserpine-treated group. Theweak effect of D5 at 18 h
after the end of inhalation exposuremay suggests some potential of
D5 for a direct or indirect modulation of prolactin secretion (DCC,
2010b).
The aged Fischer 344 rat (female rats > 20 month old) model
was utilized (DCC, 2010a) to evaluate the effect of repeated inha-
lation exposure to D5 (160 ppm, 6 h/day, for ﬁve days) on circu-
lating prolactin levels and the estrus cycle. Repeated D5 inhalation
did not signiﬁcantly affect circulating prolactin levels at the end of
the inhalation exposure on days one and ﬁve. However, the average
prolactin levels animals exposed to D5 strongly trended higher at
four and eight hours after the end of the inhalation exposure on day
ﬁve. The dopamine receptor agonist Pergolide consistently reduced
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one animal cycled throughout the six day period) suggesting that
D5 exposure may inhibit cyclicity and D5 inhalation may have
stabilized the pseudopregnant/anovulatory state as evidenced by
decreased number of estrogenic days and maintaining estrogen,
progesterone, and the estrogen:progesterone ratio. D5 inhalation
did not modulate blood levels of corticosterone or uterine weight
(DCC, 2010a).
Aged Fischer 344 rats were also utilized (DCC, 2013) to evaluate
the effect of exposure to D5 on cyclicity, prolactin, and estro-
gen:progesterone ratio. Female F344 rat aged 22 months were
exposed to D5 by inhalation (160 ppm, 6 h/day, 5 days/week for 13
weeks?). Dietary Pergolide was used as positive control. The rats
were already in a state of persistent diestrus/pseudopregnancy
when the study began. At the end of the study, pergolide admin-
istration resulted in decreased prolactin and decreased progester-
one in blood and also inhibited increased estrogen concentration
and an increased estrogen/progesterone ratio. In addition, Pergo-
lide markedly altered cyclicity increasing the incidence of proes-
trus/estrus. D5 exposure produced few changes in the markers
assessed except a marked increase in the incidence of proestrus/
estrus.
An aged F344 rat model (age 49e50 weeks at study initiation)
assessed the effects of repeated inhalation exposure to D5 (inha-
lation exposure to 160 ppm, 6 h/day, ﬁve days/week for at least 58
weeks). The study included assessment of vaginal cytology and
reproductive senescence andmonitored estrous cycle stage by daily
vaginal lavage (WIL, 2013). Serum prolactin, estradiol, progesterone
and follicle stimulating hormone were also determined at pre-
determined time-points. At the beginning of the exposure and for
the ﬁrst 90 days in the study, the rats were in an estrogenic state
20e25 % of the time. Afterwards, in control rats, age-speciﬁc
changes in the reproductive status occurred as expected during
the aging process. In the D5-exposed rats, the percent of days spent
in an estrogenic statewas increased by an average of 44% during the
ﬁrst 45-day interval and 78% during the second 45-day interval
after initiation of D5 exposure. The percentage of estrogenic days
remained increased during the third 45-day interval but the control
percentage had increased markedly during this time. Later on,
frequency of estrogenic state was not different between controls
and D5-exposed animals, as both control and D5-exposed animals
converted to a repeated pseudopregnant state characteristic of the
reproductively senescent F344 rat. Evaluation of the reproductive
tract of the animals by histopathology was consistent with animals
in pseudopregnancy and only very few differences between con-
trols and D5-exposed animals were seen. A slightly more marked
vaginal muciﬁcation and epithelial thickening in the D5-exposed
rats suggest a more advanced aging in these animals.
In vitro studies were performed to determine the ability of D5 to
stimulate prolactin release from speciﬁc cells and its afﬁnity to
dopamine receptors (DCC, 2005e; DCC, 2005d; DCC, 2009). An
initial study was performed in a cell line derived from rat pituitary
tumor (MMQ cells) to assess the potential of D5 to act as a dopa-
mine D2-receptor agonist (DCC, 2005e). MMQ cells synthesize and
secrete prolactin and contain functional dopamine D2-receptors.
Prolactin secretion in MMQ cells is inhibited by dopamine and the
extent of inhibition of prolactin secretion is thus a function of
dopamine receptor agonist concentration and potency. This model
system requires maitotoxin to elevate prolactin secretion. The
maitotoxin-induced prolactin secretion is dopamine D2-receptor
agonist-sensitive (Judd et al., 1988; Judd and MacLeod, 1991;
Forget et al., 1993). The MMQ cells used produced and secreted
prolactin, with and without induction by maitotoxin. The
maitotoxin-induced increase in prolactin secretion was sensitive to
dopamine. In support of the hypothesis that D5 may act as adopamine receptor agonist, D5 inhibited maitotoxin-induced pro-
lactin secretion by 55%.
However, a direct interaction of D5 with dopamine receptors
was not seen in a series of studies using competition experiments.
D5 did not displace dopamine receptor ligands from recombinant
human D1, D2, D3, D4,4 and D5 dopamine receptor. Competitive
binding was observed only for the dopamine D2 receptor. However,
competition was minimal and only occurred at high nominal D5
concentrations. As a consequence, the response with the D2 re-
ceptor was considered equivocal (DCC, 2009).
Another dopamine receptor binding study was initiated utiliz-
ing rat striatal membranes to assess the potential for the interaction
of D5 with the D2 receptor and the D2 receptor second messenger
protein (GTPyS) (Baker, 2010). Binding of D5 to the D2 receptor was
not observed, but a suppression of the basal activity (guanosine
50(g-thio) triphosphate (GTPgS)) occurred. An additional study
utilizing the MMQ pituitary cell line further assessed D2 receptor
activation as indicated by suppression of cellular cAMP production
following exposure to D5 (DCC, 2011). Utilizing alteration of
forskolin-induced cAMP production as the marker of dopamine D2
receptor activation demonstrated that the dopamine agonistic ef-
fect of D5 was not mediated through activation of the dopamine
receptor. The activity was not inhibited by inclusion of a dopamine
receptor antagonist and the effect was not lost following pertussis
toxin uncoupling of the G-protein and receptor. The effects of D5
appeared to be associated with competitive inhibition of forskolin
activation of adenylate cyclase.
Female rat brain striatal membranes have a high density of
dopamine receptors. Therefore, a potential interaction of D5 with
dopamine D2-receptors was studied in this isolated membrane
system. In isolated membranes from the brain striatum, exposure
to D5 did not result in activation of the dopamine D2 receptor. In
addition, the effect of D5 on iodosulpiride binding (used to deter-
mine an interactionwith the receptor and the stimulation of GTPgS
binding) showed that D5 did not have any effect on receptor acti-
vation of coupled G-protein or stimulated GTPgS binding (Baker,
2010).
The potential of D5 and its metabolites (non-
amethylcyclopentasiloxanol (nona-D5) and dimethylsilanediol) to
interfere with signaling cascades downstream to binding to the
dopamine receptor was assessed. After the binding of an agonist to
the dopamine D2-receptor, an activated receptor activates a G-
protein, which then inhibits adenylate cyclase, resulting in
decreased production of 30-50-cyclic adenosine monophosphate
(cAMP). The capacity of D5 to act as dopamine D2-receptor and/or
adenylate cyclase agonist was assessed in MMQ pituitary cells by
analyzing a possible modulation of forskolin-induced increases in
cAMP production. Transdecalin, which does not interact with the
dopamine D2 receptor or inﬂuences adenylate cyclase activity, was
included to assess a possible modulation of cAMP production by
highly lipid soluble chemicals. In these studies, while D5 and nona-
D5 attenuated forskolin-induced cAMP increases in MMQ cells,
effects of D5 was not modulated by the dopamine receptor antag-
onist Raclopride (DCC, 2011).
6. Discussion and conclusions
D5 is a highly lipophilic and volatile compound with a particular
kinetic behavior after oral administration (predicted uptake and
distribution of D5 in the form of microemulsions). D5 concentra-
tions in rodent feed are rapidly reduced due to evaporation and
feeding studies are therefore extremely difﬁcult to conduct. In
contrast, absorption of D5 after inhalation and dermal contact, two
exposure routes considered most relevant to humans, occurs by D5
molecules diffusing through cell membranes. Therefore, only
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mation on hazard properties of D5 potentially relevant to humans.
Due to the very low permeability of D5 through human skin and the
rapid evaporation of D5 when applied to skin, dermal uptake is
expected to be of low signiﬁcance with regard to the generation of
sufﬁcient plasma concentrations of D5 to produce potential sys-
temic toxicity. Moreover, due to the volatility and the surface-
spreading characteristics of D5, repeated dose dermal studies
cannot be conducted with reasonable conﬁdence. In contrast, after
inhalation, D5 is absorbed though the lungs and inhalation there-
fore is the only reasonable route of exposure resulting with a
potentially important contribution to D5 systemic availability.
As other volatile lipophilic molecules, absorbed D5 is prefer-
entially distributed to lipid-rich tissues. However, due to the high
volatility, exhalation of unchanged D5 is the major route of elimi-
nation of absorbed D5. Due to this rapid elimination by inhalation, a
bioaccumulation of D5 in lipid-rich tissues is not expected and
increased tissue levels of D5 were not observed after repeated
inhalation for six month.
Data from repeated dose inhalation studies showed that expo-
sure of experimental animal to D5 results only in a limited number
of potentially adverse effects and did not produce reproductive or
developmental toxicity. In repeated chronic exposure inhalation
studies, effects observed were limited to local effects in nasal cavity
and the lungs, reversible liver weight increases without histo-
pathological changes, and to a small increase in the incidence of
uterine adenocarcinoma in female rats after two year inhalation
exposure. D5 was determined to be not genotoxic.
In summary:
i) The respiratory tract effects (increased lung weights, sub-
mucosal inﬂammation in the lung, goblet cell proliferation)
seen in the chronic bioassay inhalation study with D5 can be
considered as a non-speciﬁc response of the respiratory tract
to repeated inhalation exposures to a mildly irritating agent.
ii) The liver weight increases observed in several toxicity
studies with D5 of shorter duration, but not in the two-year
chronic bioassay study at termination, were not accompa-
nied by histological changes in the liver. These observations
suggest that the liver weight increases represent adaptive
responses and are not adverse. Mechanistic studies conﬁrm
that D5 is a weak “phenobarbital-like” inducer of cyto-
chromes P450 in the rat. The “phenobarbital-like” enzyme
induction pattern explains the small changes in liver weights
seen in the inhalation studies.
iii) In the two-year chronic bioassay, D5 inhalation caused a
small, but (borderline) statistically signiﬁcant increase in the
incidence of uterine adenocarcinoma at the highest exposure
concentration of 160 ppm. A number of mechanistic studies
have been performed to elucidate the biological processes
which may result in uterine adenocarcinoma induction. Due
to the absence of both genotoxicity and estrogenicity of D5 in
a variety of test systems, it must be concluded that neither
genotoxicity nor a direct estrogen effect produced the slight
increase in uterine tumors. Discussed in the detail in the
accompanying paper (Klaunig et al., 2015), the likely mech-
anism for the induction of uterine adenocarcinoma is an
interference with prolactin secretion. While D5 does not
appear to be a direct dopamine agonist, the experimental
data are suggestive of an indirect interaction of D5 on the
dopamine system to alter the pituitary control of the estrus
cycle. Like other dopamine receptor agonists, D5 decreases
pituitary lactotroph release of prolactin in vitro and decreases
circulating prolactin levels in vivo. Further studies in vitro
suggest that D5 may interfere with one or more downstreamcomponents of the dopamine signal transduction pathway.
The observed effects of D5 on estrus cyclicity are consistent
with a dopamine-like effect, and further suggest that D5may
be accelerating the aging of the reproductive endocrine axis
in this strain of rat.Conﬂicts of interest
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